Q&A & Panel Discussion: Evaluating TIL Programs Through an Investor Lens to Drive Sustainable Growth
2:15 pm - Thursday 19th November 2026
- Examining how TIL leaders are balancing clinical efficacy, manufacturing complexity, and capital efficiency as investors become increasingly selective following capital-intensive cell therapy experiences
- Discussing the strategic decisions CEOs face when prioritizing indications, advancing next-generation platforms, pursuing partnerships, and managing development risk in a constrained funding environment
- Identifying the clinical, operational, and commercial milestones that most effectively rebuild investor confidence, support sustainable financing, and create long-term enterprise value
